Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,701–11,800 of 15,747
Lau, C. S., Wong, M. S., Hoo, S. P., Heng, P. Y., Phua, S. K., & Aw, T. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00257 · Cited by 3
“Manufacturers have thus recently created vaccines to induce an antibody response against SARS-CoV-2 spike proteins, with efficacies ranging from 94.1% [9] to 95% [10].”
InfluentialNuzzo, A., Manacorda, S., Sammarco, E., Sbrana, A., Bazzurri, S., Paolieri, F., Manfredi, F., Mercinelli, C., Ferrari, M., Massaro, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10060892 · Cited by 2
“Patients enrolled in our study represent a completely different population compared to those included in vaccine registered trials: in Moderna [14] and Pfizer [15] trials just 21% and 20.5% patients, respectively, had at least one comorbidity, median age was respectively 52 and 51.5 years, patients older than 65 years…”
BackgroundResultInfluentialMenter, T., Zinner, C., Berger, C. T., Went, P., & Tzankov, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285168 · Cited by 2
Trajman, A., Lachapelle-Chisholm, S., Zikos, T., Werneck, G. L., & Benedetti, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265414 · Cited by 3
T-Cell-Based Universal Dengue Vaccine Design for Robust Protective Response
Sun, Y., Yeo, A. S. L., & Moi, M. L. (2025) · Vaccines · doi:10.3390/vaccines13111118 · Cited by 2
“The two-dose regimens of BNT162b2 (Pfizer-BioNTech, Mainz, Germany) and mRNA-1273 (Moderna, Cambridge, Massachusetts, USA) against SARS-CoV-2 exhibited exceptionally strong efficacy, providing 95% and 94.1% protection against symptomatic COVID-19, respectively [42,43].”
InfluentialEvaluation of SARS-CoV-2 vaccination in pregnant and breastfeeding women
Terezia, H., Koblišková, Z., & Novák, P. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.06.002 · Cited by 2
BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
Seneviratne, C. J., Balan, P., de Alwis, R., Udawatte, N. S., Herath, T., Toh, J. Z. N., Tin, G. B., Ooi, E. E., Hong, J. L. G., & Ying, J. S. X. (2022) · International Dental Journal · doi:10.1016/j.identj.2022.09.005 · Cited by 2
“The BNT162b2 mRNA vaccine (Pfizer/BioNTech) has been shown to produce robust serum antibody responses and >95% efficacy against SARS-CoV-2.(2) Unfortunately,”
BackgroundInfluentialHalloran, M. E. (2024) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-033121-120121 · Cited by 3
“…primary placebo-controlled, observer-blinded efficacy trial of the BNT162b2 mRNA COVID-19 vaccine, one vaccine efficacy estimate was in participants from 7 days after the second dose to the end of the surveillance period, if they had no evidence of infection before that period (Polack et al. 2020).”
Effectiveness of COVID-19 vaccines in a large European hemodialysis cohort
Bernardo, A. P., Carioni, P., Stuard, S., Kotanko, P., Usvyat, L. A., Kovarova, V., Árkossy, O., Bellocchio, F., Tupputi, A., Gervasoni, F., et al. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.1037754 · Cited by 1
“Frontiers in Nephrology 08 observation was expected as the index date was coincident with the date of vaccine first dose administration and most vaccines evaluated in our study were administered as a two-dose regimen (1, 37).”
MethodCoggiola, M., Clemente, G., Frammartino, R., Grillo, E., Corradi, A., Corezzi, M., Kakaa, O., Paradisi, E., Tuffanelli, A., Pensamiento, M. C. A., et al. (2021) · La Medicina del Lavoro · doi:10.23749/mdl.v112i6.12124 · Cited by 2
“Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.”
BackgroundResultInfluentialLópez, V., Mazuecos, A., Villanego, F., et al. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.10.007 · Cited by 2
Boumendil, L., Chevret, S., Lévy, V., & Biard, L. (2024) · Statistics in Medicine · doi:10.1002/sim.10130 · Cited by 4
“…Bayesian analyses in clinical settings 31,45-49 and the upsurge of Bayesian designs in the emergent settings of therapeutic evaluation for the COVID19 pandemic, 50 their application remains scarce in several contexts, including adaptive phase III clinical trials based on a right-censored endpoint.”
Importância do gênero em doenças alérgicas
Rosário, C. S., Cardozo, C., Chong‐Neto, H. J., & Rosário, N. A. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200048 · Cited by 3
Li, M., Yang, X., Jiang, L., & Yang, D. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-056106 · Cited by 2
Korodi, M., Horváth, I., Rákosi, K., Jenei, Z. A., Hudák, G., Kákes, M., Dallos-Fejér, K., Simai, E., Páll, O., Staver, N., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.040 · Cited by 5
PSLotto: A Privacy-Enhanced COVID Lottery System
Truex, S., & Alavidze, G. (2022) · IEEE International Conference on Cognitive Machine Intelligence (CogMI) · doi:10.1109/cogmi56440.2022.00019 · Cited by 2
Xie, Y., Choi, T., & Al‐Aly, Z. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00217 · Cited by 4
Symptoms and Side Effects of the ChAdOx1 nCoV-19 vaccine (AZD1222) among healthcare workers
Javed, D., Alharbi, Y. H., Javed, A., & Iqbal, J. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2115123202 · Cited by 2
Edelman-Klapper, H., Rabinowitz, K. M., Zittan, E., Shitrit, A. B., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11071263 · Cited by 2
“AEs included local pain, headache, and fever, as described in previous studies [27,28].”
Abbasian, M. H., Rahimian, K., Mahmanzar, M., Bayat, S., Kuehu, D. L., Sisakht, M. M., Moradi, B., & Deng, Y. (2024) · Viruses · doi:10.3390/v16081331 · Cited by 2
“Thus, several new vaccine platforms such as mRNA, vector-based, inactivated, and protein-based vaccines were developed [17–19].”
BackgroundWysocki, O., Zhou, C., Rogado, J., Huddar, P., Shotton, R., Tivey, A., Albiges, L. K., Angelakas, A., Arnold, D., Aung, T., et al. (2022) · Cancers · doi:10.3390/cancers14163931 · Cited by 2
Detecting Reported Side Effects of COVID-19 Vaccines From Arabic Twitter (X) Data
Alhumayani, M. K., & Alhazmi, H. (2024) · IEEE Access · doi:10.1109/access.2024.3389655 · Cited by 4
Mo, Y., & Zheng, G. (2026) · ACS Nano · doi:10.1021/acsnano.6c09354 · Cited by 4
Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario
Jüni, P., Tuite, A. R., Bogoch, I. I., et al. (2020) · doi:10.47326/ocsat.2021.02.06.1.0 · Cited by 2
COVID-19 vaccination for patients with epilepsy: A Chinese expert consensus
Liu, X., Wang, Q., Ren, L., Fang, X., He, Z., Ding, J., Wang, K., Xu, H., Zhang, H., Song, Y., et al. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109387 · Cited by 2
Problems associated with new coronavirus infection vaccination in patients with rheumatic diseases
Vi, M., Nasonov, E. L., Lila, A. M., Gaydukova, I. Z., Inamova, O. V., & Leonchenkova, N. Y. (2022) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov108970 · Cited by 2
(2022) · doi:10.1101/2022.07.25.22277569 · Cited by 2
“Around 15% of vaccinees had fever after the second or third dose of an mRNA COVID-19 vaccine [1,9,10], while only 1-2% did so after influenza or pneumococcal vaccination [11,12].”
BackgroundEffectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease
Zhao, L., Fu, L., He, Y., Li, H. J., Song, Y., & Liu, S. (2023) · Vaccines · doi:10.3390/vaccines11020486 · Cited by 2
“Therefore, patients with cancer are usually prioritized for vaccinations but excluded from registration in clinical trials [16,17].”
BackgroundGöbel, C. H., Heinze, A., Heinze‐Kuhn, K., Karstedt, S. C., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q. A., Halwani, R., Temsah, M.-H. A., et al. (2025) · Vaccines · doi:10.3390/vaccines13020113 · Cited by 2
“Phase 3 clinical trials of various vaccine candidates provided detailed information on this topic by recording the frequency of possible side effects of the vaccination [59–61, 64, 66– 69,”
Nakatani, E., Morioka, H., Kikuchi, T., & Fukushima, M. (2024) · Cureus · doi:10.7759/cureus.75652 · Cited by 6
Pezzati, L., Giacomelli, A., Mileto, D., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.029 · Cited by 2
Special Issue on ‘Coronavirus: Vaccines and Other Therapeutics’ (2020–2021)
Basu, S. (2021) · Vaccines · doi:10.3390/vaccines9101083 · Cited by 3
Modelling and predicting online vaccination views using bow-tie decomposition
Han, Y., Bazzi, M., & Turrini, P. (2024) · Royal Society Open Science · doi:10.1098/rsos.231792 · Cited by 3
“Vaccination campaigns have drawn long-standing public attention [1,2], particularly since the outbreak of the COVID-19 pandemic [3 – 6].”
BackgroundTreatment of patients with coronavirus disease 2019 and cross‐infection in dental clinics in Korea
Lee, N., & Kim, H. (2022) · International Journal of Dental Hygiene · doi:10.1111/idh.12659 · Cited by 2
Humoral Immune Responses following COVID-19 Vaccinations among Adults in Tanzania
Bakari, M., Aboud, S., Kasubi, M. J., Mmbando, B. P., Ntinginya, N. E., Sichalwe, A. W., Ubuguyu, O., Magesa, A. S., Rutananukwa, N. L., Nyawale, H. A., et al. (2023) · Vaccines · doi:10.3390/vaccines12010022 · Cited by 2
“Apart from other adopted intervention measures, Tanzania embarked on vaccination from 31 July 2021 with four COVID-19 vaccines, namely, Johnson and Johnson (J&J), Sinopharm, Pfizer, and Moderna [7–10].”
Methodde Carvalho, M. R., Rocha, M. M. S. D. D., Bezerra, V., et al. (2023) · Case Reports in Neurological Medicine · doi:10.1155/2023/7061783 · Cited by 2
A COVID-19 Overview from the Perspective of the Brazilian Kidney Transplantation Program
Requião‐Moura, L., Foresto, R. D., de Sandes‐Freitas, T. V., et al. (2023) · COVID · doi:10.3390/covid3080083 · Cited by 2
Szalai, E., Nagy, K., Kölkedi, Z., & Csutak, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-67967-x · Cited by 2
Miyake-Stoner, S. J., Maine, C. J., Chou, A. C., Dailey, G. P., Spasova, D. S., Domingo, C. C., Sparks, J., Picarda, G. G. A., Lyerly, H. K., Crosby, E. J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.026 · Cited by 4
Cooper, D. K., Sobolik, J. S., Kovačević, J. J., Rock, C. M., Sajewski, E. T., Guest, J. L., Lopman, B. A., Jaykus, L., & León, J. S. (2023) · Applied and Environmental Microbiology · doi:10.1128/aem.00128-23 · Cited by 3
Self-citationCOVID-19 Infection in Vaccinated Healthcare Professionals
Ullah, M., Mubashir, M., Atique, H., Aslam, F., Tahir, M., & Naqvi, M. (2022) · Cureus · doi:10.7759/cureus.23386 · Cited by 4
Kim, S. R., Kim, S. K., Fujii, T., et al. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i1.177 · Cited by 2
Sousa, J. P., Roque, D., Guerreiro, C., & Teixeira, R. P. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2023.01.003 · Cited by 2
Chandrasekar, S., Phanse, Y., Riel, M., Hildebrand, R. E., Hanafy, M., Osorio, J. E., Abdelgayed, S. S., & Talaat, A. M. (2022) · Viruses · doi:10.3390/v14061262 · Cited by 2
“Vaccines were found to be highly effective and, in some instances, >95% effective at reducing hospitalization and death that was associated with COVID-19 caused by the original lineage A virus [1,2].”
Jiménez-Sepúlveda, N. J., Chico-Sánchez, P., Castro-García, J. M., Escribano-Cañadas, I., Merino, E., Ronda, E., Sánchez–Payá, J., Gras-Valentí, P., & on behalf of the COVID-19 Preventive Medicine Group (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113884 · Cited by 2
25 Models in the COVID-19 Pandemic
Imai, N., Baguelin, M., & Ferguson, N. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_37 · Cited by 2
Changing Views toward mRNA based Covid Vaccines in the Scientific Literature: 2020 - 2024
Thoene, M. A. (2024) · Polish Annals of Medicine · doi:10.29089/paom/189961 · Cited by 3
Waning vaccine response to severe COVID-19 outcomes during omicron predominance in ThailandPreprint
Intawong, K., Chariyalertsak, S., Chalom, K., Wonghirundecha, T., Kowatcharakul, W., Thongprachum, A., Chotirosniramit, N., Noppakun, K., Khwanngern, K., Teacharak, W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2449283/v1 · Cited by 2
Gail, M. H. (2021) · Statistics in Medicine · doi:10.1002/sim.8931 · Cited by 2
Yoon, S. K., Phillips, A. L., Calhoun, S., Odom, D. M., ZIEMIECKI, R. M., Jackson, L., Mckell, J., Griffin, J., Choi, J. M., Prillaman, B. A., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag141 · Cited by 5
“Studies have shown that these reactogenicity symptoms can affect the ability of healthcare workers (HCWs) and first responders (FRs) to perform their duties [13, 17].”
InfluentialGylfason, A. D., Bjarnason, A., Helgason, K. O., Rögnvaldsson, K. G., Ármannsdóttir, B., Guðmundsdóttir, I. J., & Gottfreðsson, M. (2022) · Læknablaðið · doi:10.17992/lbl.2022.04.686 · Cited by 2
Lin, C., & Chien, H.-J. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03103-z · Cited by 2
“As a result of the COVID-19 pandemic, novel vaccines based on mRNA techniques, including the Pfizer-BioNTech BNT162b2 vaccine and Moderna mRNA-1273 vaccine were developed.”
BackgroundInfluentialVaccination strategies and transmission of COVID-19: evidence across leading countries
Kim, D., & Lee, Y. J. (2021) · doi:10.47004/wp.cem.2021.3821 · Cited by 2
“7 days after the second dose, the vaccine efficacy further enhances as shown in Polack et al. (2020) and clinical trials.”
BackgroundDeletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concernPreprint
Rennick, L. J., Robinson‐McCarthy, L. R., Nambulli, S., Duprex, W. P., & McCarthy, K. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.434168 · Cited by 2
Alicandro, G., Daccò, V., Cariani, L., Contarini, M., Morlacchi, L. C., Rosazza, C., Sciarrabba, C. S., Ferraro, F., Lanfranchi, C., Orena, B. S., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.02.009 · Cited by 2
Kataoka, Y., Kimura, Y., Ikenoue, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-979599/v1 · Cited by 2
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01431-x · Cited by 6
Weide, A., Brokmann, F., Appel, B., Rosenbaum, C., Krause, J., Janke, U., Delcea, M., Weitschies, W., & Müller, S. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202300446 · Cited by 2
Panarese, A., Canossi, A., Fabiani, R., Lupi, D., Maccarone, D., Pace, P., Parzanese, I., Martínez, V., Lancione, L., Savino, V., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.10.032 · Cited by 2
“Patients who had already been infected from COVID-19, patients who received a transplant less than a year prior, patients who received treatments against rejection with rituximab and cortisone in the last 12 months, patients who received a vaccine dose right before the transplant, and patients who received a vaccine o…”
InfluentialMeyers, E., Rop, L. D., Engels, F., Gioveni, C., Coen, A., Burghgraeve, T. D., Digregorio, M., Ngoc, P. V., Clercq, N. D., Buret, L., et al. (2024) · Vaccines · doi:10.3390/vaccines12080951 · Cited by 3
“Although it was shown in clinical trials that the BNT162b2 COVID-19 vaccine was able to elicit robust immune responses in the general population, data on immune responses in an elderly population were limited, as they were underrepresented and generally healthy [2,3].”
ResultSARS-CoV2 mRNA-vaccination-induced Immunological Memory in Human Non-Lymphoid and Lymphoid Tissues
(2023) · doi:10.1101/2023.02.22.23286293 · Cited by 2
“5 Introduction Vaccination against SARS-CoV2 has been proven in large cohort studies (1, 2) a powerful strategy to protect from severe corona virus disease 2019 (COVID-19).”
BackgroundVirus-like particle-based vaccines against SARS-CoV-2
García-Silva, I., Colunga-Saucedo, M., Almendarez-Rodríguez, C., Miranda-López, C., Rosales‐Mendoza, S., & Comas‐García, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00005-x · Cited by 2
Benuni, N., Kotusov, A., Adzhieva, F., Кучер, А., Tolmacheva, K. A., Dushuk, V. N., & Maslennikov, R. V. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2022-32-3-23-28 · Cited by 2
Ergi, D. G., Kahraman, Ü., Kayalı, G. A., Durmaz, S., Balcıoğlu, Ö., Engin, Ç., Yağmur, B., Nalbantgil, S., Çiçek, C., Özbaran, M., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13223460 · Cited by 2
AŞILAMA KONULU KAMU POLİTİKALARININ KARŞILAŞTIRMALI BİR ANALİZİ
SEMERCİ, H., & Yıldız, M. (2023) · Hacettepe Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi · doi:10.17065/huniibf.1099139 · Cited by 5
COVID-19 vaccination in peritoneal dialysis patients
Htay, H., Foo, M. W. Y., Gan, S. S. W., Jayaballa, M., Oei, E. L., Tan, M. S. H., Wang, W., Wu, S. Y., & Tan, C. S. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03302-5 · Cited by 2
“[11] Similarly, in the present study, the adverse effects of the vaccine were 25% and 27% after the first and second dose of the vaccine, respectively.”
BackgroundTopal, Ü., Yılmaz, G., & Şahin, A. S. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.12.016 · Cited by 2
Clari, M., Godono, A., Albanesi, B., Casabona, E., Comoretto, R. I., Mansour, I., Conti, A., Dimonte, V., & Ciocan, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052944 · Cited by 2
“Despite the proven efficacy in terms of reducing infection rates, mortality and symptom severity of both m-RNA and viral vector vaccines [8,9], the actual challenge faced by policymakers is to promote the vaccination campaign in order to achieve optimal immunization coverage.”
BackgroundHu, J., & Mo, Z. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023100 · Cited by 3
Prabhu, R., Prabhu, G., Htay, M. N. N., Thundakattil, A. V., Moe, S., & Das, S. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11254-1 · Cited by 2
“…quickly translated by antigen-presenting cells (APC) in draining lymph nodes as well as at the injection site, where it triggered strong in vivo adaptive as well as humoral immune responses by activating more CD8 + T-cells and generating more RBD-specific and neutralizing antibodies in humans [37].”
No Evidence That Analgesic Use after COVID-19 Vaccination Negatively Impacts Antibody Responses
LaFleur, B., White, L. M., Dake, M. D., Nikolich‐Žugich, J., Sprissler, R. S., & Bhattacharya, D. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300090 · Cited by 2
van Vuren, P. J., McAuley, A. J., Kuiper, M. J., Singanallur, N. B., Bruce, M. P., Riddell, S., Goldie, S., Mangalaganesh, S., Chahal, S., Drew, T. W., et al. (2022) · doi:10.1101/2022.03.03.481940 · Cited by 9
Gandjour, A. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08726-4 · Cited by 2
Inducing Quality Immune Response to Respiratory Viruses May Not Be a Simple Task
Ranga, U., & Asokan, M. (2021) · Current Science · doi:10.18520/cs/v120/i8/1315-1323 · Cited by 1
Gomes, D., Beyerlein, A., Katz, K., Hoelscher, G., Nennstiel, U., Liebl, B., Ueberla, K., & von Kries, R. (2021) · medRxiv · doi:10.1101/2021.08.19.21262266 · Cited by 1
Singh, R. S., Singh, A. K., Masih, G. D., Batra, G., Sharma, A. R., Joshi, R., Prakash, A., Suroy, B., Sarma, P., Prajapat, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16813 · Cited by 3
Keijser, J. B. D., Stalman, E. W., Wieske, L., Steenhuis, M., van Dam, K. P. J., Kummer, L. Y. L., van Kempen, Z. L. E., Killestein, J., Volkers, A., Tas, S. W., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105620 · Cited by 3
Younes, S. N., Nicolai, E., Pieri, M., Bernardini, S., Daas, H. I., Al‐Sadeq, D. W., Younes, N., Shurrab, F. M., Nizamuddin, P. B., Amanullah, F. H., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13290 · Cited by 3
Kim, J.-E. C., Dahlen, H. M., Dupervil, D., Ihongbe, T. O., Moffett, K. W., Hoffman, B., Denison, B., Kranzler, E. C., Yu, K., Margolis, K. A., et al. (2025) · Health Communication · doi:10.1080/10410236.2025.2449713 · Cited by 3
“Researchers have confirmed COVID-19 vaccine safety and efficacy against reducing risk of COVID-19 hospitalization and death (Baden et al., 2021; Christie et al., 2021; Moghadas et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Thomas et al., 2021).”
COVID-19 Vaccine Effectiveness among Patients with Psoriatic Disease: A Population-Based Study
Gazitt, T., Eder, L., Saliba, W., Stein, N., Feldhamer, I., Cohen, A. D., & Zisman, D. (2024) · Vaccines · doi:10.3390/vaccines12050453 · Cited by 2
“…and authorization of novel messenger RNA (mRNA) vaccines that have since proven to be immunogenic and effective in the immunocompetent population [1,2] Although patients with autoimmune inflammatory rheumatic diseases (AIIRD) were prioritized in terms of receiving COVID-19 vaccines, in order to…”
BackgroundReardon, J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0016 · Cited by 2
The impact of COVID-19 on patients with stroke: an integrative review
Ruksakulpiwat, S. (2021) · Journal of Health Research · doi:10.1108/jhr-12-2020-0615 · Cited by 2
Ishihara, Y., Naruse, H., Fujigaki, H., Murakami, R., Ando, T., Sakurai, K., Uehara, K., Shimomae, K., Sakaguchi, E., Hattori, H., et al. (2024) · Vaccines · doi:10.3390/vaccines12070786 · Cited by 2
“The primary series of the COVID-19 vaccines has shown excellent efficacy in clinical trials [15,16] and effectiveness in real-world settings [17].”
BackgroundNova mutação no gene STAT1 associada com candidíase mucocutânea crônica
Jobim, M., Puel, A., Ewald, G. M., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200054 · Cited by 2
Etna, M. P., Fuoco, C., Severa, M., Ricci, D., Sinigaglia, A., Lucca, C., Cairo, G., Bottazzi, B., Garlanda, C., Palamara, A. T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1651095 · Cited by 3
Torresi, J., Earnest, L., Fernandez‐Ruiz, D., Edeling, M. A., Montoya, J., Yap, A. H. Y., Wong, C. Y., Holz, L. E., Gras, S., Collett, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4503306/v1 · Cited by 2
Immunogenicity of HIV-1 Env mRNA and Env-Gag VLP mRNA Vaccines in Mice
Ma, Q., Yang, J., Zhang, X., Li, H., Hao, Y., & Feng, X. (2025) · Vaccines · doi:10.3390/vaccines13010084 · Cited by 2
(2023) · doi:10.1101/2023.03.01.23286513 · Cited by 2
“The initial clinical trials of the SARS-CoV-2 mRNA vaccines (BNT162b2 Pfizer/BioNTech and mRNA-1273 Moderna) excluded immunocompromised patients (4, 5), raising concerns about how to optimally protect these vulnerable patients.”
BackgroundPérez-Milena, A. (2021) · Comunidad · doi:10.55783/comunidad.230101 · Cited by 2
The evolution of pharmacovigilance ecosystems: Does Moore's law invite the use of Occam's razor?
Mueller, M., Lewis, D. J., & Alexe, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15573 · Cited by 2
“In this case, simplification took the form of the issuing of conditional marketing authorizations, based on high vaccine efficacy and an adequate safety profile.(58) It is recognized that this was a unique situation, but wider application of the lessons learned could well be beneficial for all stakeholders, and in our…”
BackgroundRecent Updates on mRNA Vaccines
Sydow, E., Mustafa, A. S., Hanif, A., Tunio, J. H., & Hanif, S. N. M. (2022) · Vaccines · doi:10.3390/vaccines10081209 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.